ZSAN Zosano Pharma Corporation

1.78
-0.01  -1%
Previous Close 1.79
Open 1.8
52 Week Low 0.405
52 Week High 2.45
Market Cap $170,208,563
Shares 95,622,788
Float 92,783,421
Enterprise Value $177,393,562
Volume 5,277,191
Av. Daily Volume 5,848,724
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Qtrypta (M207)
Migraine
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
C213
Cluster headache
Phase 2/3
Phase 2/3
Phase 2/3 trial initiation announced October 24, 2019.
M207
Migraine
Phase 3
Phase 3
Phase 3 trial data due released February 13, 2017 - primary endpoints met.

Latest News

  1. FREMONT, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:40 am ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma
    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established…

    FREMONT, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:40 am ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

    Zosano Contact:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    PR Contacts:

    Sylvia Wheeler or Alexandra Santos

    or

    Primary Logo

    View Full Article Hide Full Article
  2. FREMONT, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 pm ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma
    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with…

    FREMONT, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 pm ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

    Zosano Contact:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    PR Contacts:

    Sylvia Wheeler or Alexandra Santos

    or

    Primary Logo

    View Full Article Hide Full Article
  3. FREMONT, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8 million, before deducting offering expenses payable by Zosano.  The offering is expected to close on or about September 3, 2020, subject to the satisfaction of customary closing conditions.

    BTIG is the sole book-running manager for the offering. 

    A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on April 16, 2020. The offering is being made only by means of a written…

    FREMONT, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8 million, before deducting offering expenses payable by Zosano.  The offering is expected to close on or about September 3, 2020, subject to the satisfaction of customary closing conditions.

    BTIG is the sole book-running manager for the offering. 

    A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on April 16, 2020. The offering is being made only by means of a written prospectus and prospectus supplement that will form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from BTIG, LLC, 65 East 55th Street, New York, NY, 10022, by email at or by telephone at (212) 593-7555.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Zosano, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Zosano's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. Zosano undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Zosano's business in general, please refer to Zosano's preliminary prospectus supplement filed with the SEC on August 31, 2020, including the documents incorporated by reference therein, which include Zosano's Annual Report on Form 10-K filed with the SEC on March 13, 2020, Zosano's Quarterly Reports on Form 10-Q filed with the SEC on May 14, 2020 and August 6, 2020, and Zosano's other periodic reports filed with the SEC.

    Zosano Contact:

    Christine Matthews

    Chief Financial Officer

    (510) 745-1200

    PR Contact:

    Sylvia Wheeler and Alexandra Santos

    /

    Primary Logo

    View Full Article Hide Full Article
  4. FREMONT, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

    BTIG is the sole book-running manager for the proposed offering.

    A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on April 16, 2020. The offering is being made…

    FREMONT, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

    BTIG is the sole book-running manager for the proposed offering.

    A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on April 16, 2020. The offering is being made only by means of a written prospectus and prospectus supplement that will form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, from BTIG, LLC, 65 East 55th Street, New York, NY, 10022, by email at or by telephone at (212) 593-7555.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Zosano, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Zosano's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. Zosano undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Zosano's business in general, please refer to Zosano's preliminary prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Zosano's Annual Report on Form 10-K filed with the SEC on March 13, 2020, Zosano's Quarterly Reports on Form 10-Q filed with the SEC on May 14, 2020 and August 6, 2020, and Zosano's other periodic reports filed with the SEC.

    Zosano Contact:

    Christine Matthews

    Chief Financial Officer

    (510) 745-1200

    PR Contact:

    Sylvia Wheeler and Alexandra Santos

    /

    Primary Logo

    View Full Article Hide Full Article
  5. FREMONT, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that develops and commercializes innovative therapies for patients addressing unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines.

    "Our agreement with Mitsubishi Tanabe Pharma Corporation allows us to combine our proprietary transdermal microneedle drug delivery platform with Mitsubishi Tanabe Pharma Corporation's drug development candidate," said Steven Lo…

    FREMONT, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that develops and commercializes innovative therapies for patients addressing unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines.

    "Our agreement with Mitsubishi Tanabe Pharma Corporation allows us to combine our proprietary transdermal microneedle drug delivery platform with Mitsubishi Tanabe Pharma Corporation's drug development candidate," said Steven Lo, President and CEO of Zosano.  "We expect through this partnership, to demonstrate the broad applicability of our platform for making a difference in the lives of patients when combined with pharmaceutical products that address significant unmet medical needs." 

    Under the agreement, Zosano will evaluate the feasibility of formulating a pharmaceutical agent being developed by Mitsubishi Tanabe Pharma Corporation for administration in humans, with its proprietary microneedle patch system.  Defined research and development activities will include both in vitro and in vivo phases.   Mitsubishi Tanabe Pharma Corporation receives the right to exercise an option to negotiate an exclusive license to the relevant Zosano technologies in the defined field, which exercise will be dependent on the outcome of the studies.  Financial terms and the identity of the Mitsubishi Tanabe Pharma Corporation molecule and development program are not disclosed.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding the feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, our goals and expectations with respect to the feasibility study agreement and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the Zosano's ability to obtain additional cash resources to continue operations for the remainder of 2020, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Zosano's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

    Zosano Contact:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    PR Contacts:

    Sylvia Wheeler or Alexandra Santos

    or

    Primary Logo

    View Full Article Hide Full Article
View All Zosano Pharma Corporation News